Clinical Trial Update: Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the addition of fulvestrant to erlotinib in stage IIIB/IV non-small cell lung cancer was terminated; results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)
• Fulvestrant (fulvestrant)

Snippet

Sponsor: Lyudmila Bazhenova, M.D. | Conditions: Non Small Cell Lung Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2017-06-06